Sirnaomics has a robust pipeline of biopharmaceutical therapies built through the in-house development of innovative product candidates and novel RNAi and mRNA delivery platforms. We are the first company to achieve positive Phase Ⅱa clinical outcomes in oncology for an RNAi therapeutic.
We have 16 therapeutic candidates in the preclinical stage through Phase Ⅱ clinical trials in the U.S. and China, addressing a wide range of disease areas, from oncology and fibrotic disease, to cardiometabolic, viral and liver disease. We are focused on developing new delivery platforms for RNA therapeutics to maintain and broaden the scope of our product pipeline and overcome the limitations of conventional RNA delivery tools.
Our proprietary delivery platforms include our PNP delivery platform for local or systemic administration of RNAi therapeutics, our GalNAc-RNAi delivery platform for administration of RNAi therapeutics to the liver, our peptide docking vehicle (PDOV) platform for improved delivery and release of siRNAs into the hepatocytes in the liver and our PLNP delivery platform for administration of mRNA vaccines and therapeutics. We own nine issued patents in China, nine issued patents in the U.S., two issued patents in Europe, and have 119 patent applications pending.
Headquartered in the U.S., we are led by a visionary management team with deep experience and capabilities in discovering, developing, and commercializing RNA therapeutics with decades of experience in pharmaceutical research and development experience at the world’s leading pharmaceutical companies and research institutions in China and the U.S.
Drug Delivery Systems
Our highly innovative RNA delivery platforms distinguish Sirnaomics from other drug development companies. Delivery platforms are critical to the intact delivery of RNA therapeutics to the cells where they are needed. Our proprietary PNP and novel GalNAc delivery platforms provide advantages over conventional delivery platforms.